Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

STRENGTHENED BALANCE SHEET RAISING APPROXIMATELY $64 MILLION IN GROSS PROCEEDS IN JULY 2025; CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS NOW SUFFICIENT TO FUND OPERATIONS INTO THE FIRST HALF OF 2028

ABSCI REPORTS BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

BARCELONA, SPAIN AND VANCOUVER, WASH., AUG. 07, 2025 (GLOBE NEWSWIRE) -- ALMIRALL (BME: ALM), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON MEDICAL DERMATOLOGY, AND ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE EXPANSION OF THEIR ONGOING AI DRUG DISCOVERY COLLABORATION WITH ALMIRALL'S SELECTION OF A SECOND TARGET AIMED AT DERMATOLOGICAL INDICATIONS.

ALMIRALL AND ABSCI EXPAND AI DRUG CREATION COLLABORATION ADDING A SECOND DERMATOLOGY TARGET

VANCOUVER, WASH. AND NEW YORK, JULY 30, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE DESIGN, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER 2025 AFTER MARKET CLOSE ON TUESDAY, AUGUST 12, 2025.

ABSCI TO REPORT BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON AUGUST 12, 2025

VANCOUVER, WASH., JULY 24, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI) (ABSCI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING POTENTIAL BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 16,670,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.00 PER SHARE, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS. IN ADDITION, ABSCI HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 2,500,500 SHARES OF ITS COMMON STOCK ON THE SAME TERMS AND CONDITIONS. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $50 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. ALL OF THE SHARES IN THE OFFERING ARE TO BE SOLD BY ABSCI.

ABSCI ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

VANCOUVER, WASH., JULY 24, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI) (ABSCI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING POTENTIAL BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $50 MILLION OF SHARES OF ITS COMMON STOCK. ABSCI ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $7.5 MILLION OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES IN THE PROPOSED OFFERING ARE TO BE SOLD BY ABSCI.

ABSCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

VANCOUVER, WASH., JULY 07, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE APPOINTMENT OF VETERAN BIOPHARMACEUTICAL EXECUTIVE MARY SZELA TO ITS BOARD OF DIRECTORS.

ABSCI APPOINTS BIOPHARMA LEADER MARY SZELA TO BOARD OF DIRECTORS

VANCOUVER, WASH. AND NEW YORK, MAY 20, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE DESIGN, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES.

ABSCI TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

INITIATED DOSING OF PARTICIPANTS IN THE FIRST-IN-HUMAN STUDY OF ABS-101 (ANTI-TL1A ANTIBODY), WITH INTERIM DATA EXPECTED IN THE SECOND HALF OF 2025 ABS-201 (ANTI-PRLR) NON-HUMAN PRIMATE (NHP) DATA DEMONSTRATE EXTENDED HALF LIFE AND HIGH SUBCUTANEOUS BIOAVAILABILITY; ANTICIPATE PHASE 1 INITIATION IN EARLY 2026 CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS SUFFICIENT TO FUND OPERATIONS INTO THE FIRST HALF OF 2027 VANCOUVER, WASH. AND NEW YORK, MAY 13, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE DESIGN, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED MARCH31, 2025.

ABSCI REPORTS BUSINESS UPDATES AND FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS

ABSCI BECOMES CLINICAL STAGE COMPANY WITH ABS-101, FIRST AI-DESIGNED BIOLOGIC FOR IBD, BEGINNING PHASE 1 TRIAL PRECLINICAL DATA FOR ABS-101 DEMONSTRATES HIGH POTENCY AND POTENTIAL FOR QUARTERLY DOSING, AN IMPROVEMENT IN EFFICACY AND CONVENIENCE OVER FIRST-GENERATION ANTI-TL1AS INTERIM DATA ANTICIPATED IN THE SECOND HALF OF 2025 VANCOUVER, WASH., MAY 13, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI) A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THAT THE FIRST HEALTHY VOLUNTEERS HAVE BEEN DOSED IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 1 STUDY EVALUATING ABS-101, AN INVESTIGATIONAL ANTI-TL1A ANTIBODY ENGINEERED WITH ABSCI'S GENERATIVE AI PLATFORM.

ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

VANCOUVER, WASH. AND NEW YORK, APRIL 14, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A DATA-FIRST GENERATIVE AI DRUG CREATION COMPANY, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER 2025 AFTER MARKET CLOSE ON TUESDAY, MAY 13, 2025.

Absci Corporation

ABSI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Absci Corporation

ABSI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABSI